All In Biotech

Drug Trial Radar · NCT03448978

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

32

Actual

Start

Mar 8, 2018

Primary completion

Apr 19, 2021

Study completion Jun 3, 2021

Sponsor

Lead sponsor
Cartesian TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • Descartes-08Biological

    autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor

  • FludarabineDrug

    intravenous fludarabine

  • CyclophosphamideDrug

    intravenous cyclophosphamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 2 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Virgina Cancer Specialists

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.